So, when Yang Jing learned about this bad news, he was a little stunned and couldn't speak for a long time.

"Cole, you must have a way, right? You must have a way to help Vivian, right? I know you, I know you, I have followed you thirteen years ago, so this time you must help me and help me keep Vivian..."

From Yang Jing's expression, Old Mike saw something, but he still begged Yang Jing. At this time, Yang Jing was almost his only spiritual pillar.

Especially over the years, this person who is nearly twenty years younger than him is so magical. He started with a mere 30 million US dollars and spent thirteen years to increase the 30 million US dollars more than 10,000 times, and also developed a small dragon fund into the largest and most terrifying fund in the world.

How could such a nearly omnipotent boss not be able to treat Vivian?

"Hey, Mike, please calm down first." Yang Jing came to his senses, patted the old man's shoulder and said softly, "Can you tell me about Vivian's situation? I need to understand it from beginning to end so that I can find a way to solve the problem. I can't help you in this way."

Yang Jing's words immediately made Old Mike's eyes lit up again. He grabbed Yang Jing's hand tightly and asked in an extremely eager tone: "Cole, can you really save Vivian's life?"

Yang Jing did not nod or shook his head. He didn't know whether his acupuncture could completely treat this terminal illness, so he didn't dare to give Old Mike any guarantee.

At this time, it is definitely an extremely wrong approach. If the guarantee is not completed, the blow to Old Mike will be fatal. Yang Jing doesn't want his capable assistant to be disloyal from him because of a small guarantee.

"Mike, I don't know Vivian's situation now, so I need you to tell me. Mike, you shouldn't be like this at this time, because if you want to save Vivian, you can't panic first. You don't even have the confidence to save Vivian. Can you still count on others? So, what you need to do most now is to cheer up yourself up so that you can have enough strength to save your Vivian."

Old Mike took a deep breath, bit his cheek, then nodded heavily and raised his head again.

"Cole, Vivian felt a little uncomfortable at the beginning of last month, so he went to the hospital for examination. The doctor gave a result that the chronic myeloid leukemia with a positive chromosome in Philadelphia. The doctor said that Vivian's disease is in the chronic phase and is not yet transformed. However, according to the results of the examination, although Vivian discovered this disease at the beginning of the chronic phase, if there is no special control method and medicine, he will enter the transformation phase in at most two years. By that time, it is almost helpless."

Although Old Mike's tone was very sad, his words were clearly organized. It can be seen that he was now starting to cheer up.

Yang Jing asked, "So, have you applied for bone marrow matching?"

If this disease is completely cured, bone marrow transplantation is the best way to get rid of this disease. Of course, if Mike and Vivian can have another child, the treatment of stem cells in the umbilical cord blood will be better than bone marrow transplantation. But with the age of Mike and Vivian, it is obviously impossible to have another child. Vivian has already had menopause, let alone her body does not allow another child.

Therefore, bone marrow transplantation is the best medical method at present.

But similarly, even in the United States, bone marrow transplantation is not just transplanted. It is difficult to match bone marrow even in the United States. It is not rare to not match the type in one or two years.

"Well, I applied, but I'm afraid there's no hope." Old Mike said in a heavy mood. "Bone marrow matching depends on luck. It's normal not to be worth it. Only few people can find the right bone marrow for transplantation. Sorry, Cole, I just said that I wanted to quit because I was worried that I couldn't find the right bone marrow. In that case, I can only accompany Vivian to walk the last part of my life with her."

Yang Jing patted the back of the old man's hand and said, "Mike, I can understand your mood. If it were me, I would have done this too. So, is Vivian just undergoing medication now?"

"Well, she mainly uses Malilan tablets to control it now, but the drug has a lot of side effects. Vivian has been having a hard time during this period."

"Malilan Tablets?" Yang Jing hesitated for a moment, and then realized that this drug had another name in China, that is Bulkan Tablets. Before Swiss Novartis Pharmaceutical developed Gleevec, this drug and hydroxyurea sulfate were the best medicines to control leukemia.

However, the toxic side effects of these two drugs are very great, and the therapeutic effect is far less than that of the famous Gleevec in later generations.

Because Yang Jing watched the movie "I Am Not a God of Medicine" last year and was very moved, he specifically checked the source of the drug "Glein" in the movie. He knew very well about the real anti-leukemia miracle drug Gleevec.

However, although Gleev's research and development has already made some progress, it is only just an error. It is still six years before the real Gleevec conducts the first human experiment.

Moreover, during this period, even Novartis Pharmaceuticals had not been established. It was not until 1996 that the Swiss pharmaceutical companies Ciba-Geigy and Sandoz would merge to become Novartis. But it is obvious that without the special control drug Gleevec, it would be difficult for Vivian to last for two or three years.

But it is obviously not easy to develop Gleevec at once. Gleevec's research and development has gone through a long and tortuous road.

Since the discovery of leukemia, humans have been fighting against this incurable disease. In the 1950s and 1960s, mainstream academic circles generally believed that "viruses are the main cause of tumors." At this time, Norwell and Hungerford from the University of Pennsylvania's Oncology Institute began to do a "rebellious" thing, trying to find changes in genetic material in tumor cells.

In 1973, Dr. Janet Raleigh, a female PhD from the University of Chicago, also joined the study.

Until the 1980s, with the rise of oncogene research, New Zealand scientist Dr. Annielese discovered a homologous gene sequence of human and mouse leukemia virus, C-ABL, which was translocated from chromosome 9 to the long arm of chromosome 22. This conclusion shows that the translocation of C-ABL led to the occurrence of CML.

From Dr. Norwell's discovery of the Philadelphia chromosome in 1960, to Dr. Janet Rawley in 1973, it was clear that the Philadelphia chromosome was caused by chromosomal translocation. Finally, in 1982, Dr. Annielese discovered that the oncogene C-ABL translocation and fused with BCR to continuously activate the tyrosine kinase, which eventually led to the occurrence of CML, which lasted for 22 years.

The cause of leukemia has been found, but it has been nearly twenty years since we wanted to find a solution to this pathology.

In 1993, Brian Drucker, who was only 38 years old, came to Oregon University of Health Sciences in Portland for scientific research on CML. During this period, Drucker and his colleagues in Boston used specially designed antibodies to develop a new method to determine the activity of BCR-ABL enzymes. This method is a priceless tool to evaluate potential therapies for chronic myeloid leukemia. While finding this method, Drucker must compete with competitors from other research centers to be the first to find a drug that can inactivate key enzymes to inhibit cancer and allow the remaining healthy tissue to survive.

Nick Leiden, a biochemist at the Swiss pharmaceutical company Ciba-Geigy, is an old friend of Drucker. Nick called Drucker and told Drucker that their company had something Drucker was looking for.

The drug is called STI571, which is the name Gleevec during its development. Although it was accidentally synthesized by chemists at Ciba-Geigy while looking for a new anti-inflammatory drug, in vitro experiments, researchers found that STI571 can inhibit the activity of enzymes. However, they are not sure how to use the compound.

In other words, at this critical moment, Ciba-Geigy has a key enzyme, and Drucker masters how to use this key enzyme. Once the two meet, it means that when the dry fire encounters fire, a violent chemical reaction immediately occurs.

In August 1993, Drucker received the first batch of liquid STI571 samples and other candidate compounds from Switzerland. He used the enzyme detection technology he assisted in developing, and confirmed that STI571 can play a strong inhibitory role in BCR-ABL enzyme.

However, although the experiments conducted in the laboratory were very successful, the results of the experiments on animals were not satisfactory.

However, in 1997, Drucker still published a large number of related papers with his collaborators from Portland and Switzerland. He believed that the compound STI571 was ready for human trials. However, at this time, Novartis did not agree to conduct human trials because in previous animal experiments, it was always impossible to solve the phenomenon that dogs who received intravenous administration would have blood clots at the end of the catheter, and when large doses were injected into the dogs, these animals showed signs of liver damage.

Under the premise that this situation cannot be resolved, Novartis even suggested completely abandoning the project.

However, Novartis' retreat did not make Drucker retreat. After all, chemotherapy would also be destructive to the canine body. So he bypassed Novartis and filed a declaration directly with the U.S. Food and Drug Administration (FDA). In June 1998, after obtaining FDA approval, Drucker used STI571 to treat a 68-year-old Oregon man with chronic myeloid leukemia.

The effect of clinical treatment is naturally fine. The side effects that occurred in experiments on canine animals have disappeared. It can be said that this first clinical trial has achieved a successful success.

As more and more leukemia patients voluntarily join clinical trials, this drug has indeed achieved better results. So in 2001, Novartis submitted the new drug application report to the FDA, and it was approved within two and a half months - this is the fastest drug review in the history of the FDA so far. It is also one of the few first-line clinical drugs that have only passed the Phase I clinical trial and were directly approved in the form of a "green channel".

In May 2001, the US government announced that the new drug, Novartis, was named Gleevec in the North American market and Glivec in Europe, would be used to treat patients with chronic myeloid leukemia.

This is the entire process of Gleevec's birth. It took nearly half a century to go through, and the total research funding exceeded 5 billion US dollars!

This drug is indeed the best drug for treating leukemia. Many leukemia patients in later generations can generally survive for five or six years even if they do not undergo bone marrow transplantation after using this drug. Some patients can even survive for ten or twenty years.

Of course, the price of this drug is also very expensive. At least in China, this drug is definitely not something that ordinary people can afford.

"I Am Not a God of Medicine", but it was filmed based on various things caused by this drug in China.

However, in this era, Gleevec has not yet developed it...
Chapter completed!